| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ammar Muhammad, Eva C Coopmans, Patric J D Delhanty, Alof H G Dallenga, Iain K Haitsma, Joseph A M J L Janssen, Aart J van der Lely, Sebastian J C M M Negger. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study. European journal of endocrinology. vol 179. issue 5. 2018-10-19. PMID:30076159. |
efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: pape extension study. |
2018-10-19 |
2023-08-13 |
Not clear |
| Hande Mefkure Ozkaya, Nil Comunoglu, Muge Sayitoglu, Fatma Ela Keskin, Sinem Firtina, Khusan Khodzhaev, Tugce Apaydin, Nurperi Gazioglu, Necmettin Tanriover, Buge Oz, Pinar Kadiogl. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Pituitary. vol 21. issue 4. 2018-10-16. PMID:29455389. |
germline mutations of aryl hydrocarbon receptor-interacting protein (aip) gene and somatostatin receptor 1-5 and aip immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. |
2018-10-16 |
2023-08-13 |
Not clear |
| Hande Mefkure Ozkaya, Nil Comunoglu, Muge Sayitoglu, Fatma Ela Keskin, Sinem Firtina, Khusan Khodzhaev, Tugce Apaydin, Nurperi Gazioglu, Necmettin Tanriover, Buge Oz, Pinar Kadiogl. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Pituitary. vol 21. issue 4. 2018-10-16. PMID:29455389. |
to determine aryl hydrocarbon interacting protein (aip) gene variations and aip and somatostatin receptor (sstr) 1-5 immunostaining in patients with apparently sporadic acromegaly with poor versus good response to somatostatin analogues (srls). |
2018-10-16 |
2023-08-13 |
Not clear |
| M Ragonese, S Grottoli, P Maffei, A Alibrandi, M R Ambrosio, G Arnaldi, A Bianchi, S Puglisi, M C Zatelli, L De Marinis, E Ghigo, A Giustina, F Maffezzoni, C Martini, L Trementino, S Cannav. How to improve effectiveness of pegvisomant treatment in acromegalic patients. Journal of endocrinological investigation. vol 41. issue 5. 2018-10-09. PMID:29080965. |
pegvisomant (pegv) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. |
2018-10-09 |
2023-08-13 |
Not clear |
| Sabrina Chiloiro, Gherardo Mazziotti, Antonella Giampietro, Antonio Bianchi, Stefano Frara, Marilda Mormando, Alfredo Pontecorvi, Andrea Giustina, Laura De Marini. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary. vol 21. issue 3. 2018-09-24. PMID:29397538. |
effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. |
2018-09-24 |
2023-08-13 |
Not clear |
| Sabrina Chiloiro, Gherardo Mazziotti, Antonella Giampietro, Antonio Bianchi, Stefano Frara, Marilda Mormando, Alfredo Pontecorvi, Andrea Giustina, Laura De Marini. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary. vol 21. issue 3. 2018-09-24. PMID:29397538. |
somatostatin receptor ligands (srls) and pegvisomant (pegv) are used for treatment of acromegaly and there is evidence that both drugs may exert direct effects on peripheral targets regardless of biochemical control of disease. |
2018-09-24 |
2023-08-13 |
Not clear |
| F K Dagistanli, H M Ozkaya, B Kucukyoruk, H Biceroglu, D Metin, N Gazioglu, B Oz, P Kadioglu, M Oztur. Preoperative Somatostatin Analogue Treatment Might Trigger Apoptosis and Autophagy in Tumor Tissues of Patients with Acromegaly: A Pilot Study. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 126. issue 3. 2018-09-05. PMID:27322826. |
preoperative somatostatin analogue treatment might trigger apoptosis and autophagy in tumor tissues of patients with acromegaly: a pilot study. |
2018-09-05 |
2023-08-13 |
Not clear |
| F K Dagistanli, H M Ozkaya, B Kucukyoruk, H Biceroglu, D Metin, N Gazioglu, B Oz, P Kadioglu, M Oztur. Preoperative Somatostatin Analogue Treatment Might Trigger Apoptosis and Autophagy in Tumor Tissues of Patients with Acromegaly: A Pilot Study. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 126. issue 3. 2018-09-05. PMID:27322826. |
to evaluate the effect of preoperative somatostatin analog (srl) treatment on proteins associated with apoptosis and autophagy in patients with acromegaly and to determine factors correlating with these parameters. |
2018-09-05 |
2023-08-13 |
Not clear |
| Jeremy Streuli, Alan G Harris, Cecilia Cottiny, Florent Allagnat, Adrian F Daly, Eric Grouzmann, Karim Abi. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors. Neuropeptides. vol 68. 2018-09-05. PMID:29523357. |
somatostatin analogs (ssas) are first-line medical therapy for the treatment of acromegaly and neuroendocrine tumors that express somatostatin receptors (sstr). |
2018-09-05 |
2023-08-13 |
Not clear |
| Mehrnaz Imani, Mohammad Ebrahim Khamseh, Poopak Asadi, Mohammad Ghorbani, Hamideh Akbari, Fariba Alaei-Shahmiri, Maryam Honardoost, Mahmoud Reza Kaynama, Mojtaba Male. COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 24. issue 6. 2018-08-23. PMID:29949429. |
comparison of cabergoline versus raloxifene add-on therapy to long-acting somatostatin analogue in patients with inadequately controlled acromegaly: a randomized open label clinical trial. |
2018-08-23 |
2023-08-13 |
Not clear |
| Mehrnaz Imani, Mohammad Ebrahim Khamseh, Poopak Asadi, Mohammad Ghorbani, Hamideh Akbari, Fariba Alaei-Shahmiri, Maryam Honardoost, Mahmoud Reza Kaynama, Mojtaba Male. COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 24. issue 6. 2018-08-23. PMID:29949429. |
the present study aimed to evaluate the efficacy of add-on therapy of cabergoline versus raloxifene to long-acting somatostatin analogues (sas) in patients with inadequately controlled acromegaly. |
2018-08-23 |
2023-08-13 |
Not clear |
| Seo Young Lee, Jung Hee Kim, Ji Hyun Lee, Yong Hwy Kim, Hyang Jin Cha, Sang Wan Kim, Sun Ha Paek, Chan Soo Shi. The efficacy of medical treatment in patients with acromegaly in clinical practice. Endocrine journal. vol 65. issue 1. 2018-08-17. PMID:28931779. |
although somatostatin analogues (ssas) are recommended as the first-line medical therapy for acromegaly, dopamine agonists (das) are also a therapeutic option for treatment. |
2018-08-17 |
2023-08-13 |
Not clear |
| A Ciresi, S Radellini, V Guarnotta, C Giordan. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report. BMC endocrine disorders. vol 18. issue 1. 2018-08-17. PMID:29361932. |
the approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (srls) should be strictly tailored. |
2018-08-17 |
2023-08-13 |
Not clear |
| Sho Tanaka, Akira Haketa, Shun Yamamuro, Toshiko Suzuki, Hiroki Kobayashi, Yoshinari Hatanaka, Takahiro Ueno, Noboru Fukuda, Masanori Abe, Atsuo Yoshino, Masayoshi Som. Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report. Journal of diabetes investigation. vol 9. issue 1. 2018-08-15. PMID:28390105. |
whether somatostatin analogs for acromegaly improve or worsen a patient's glycemic profile is controversial. |
2018-08-15 |
2023-08-13 |
Not clear |
| Sho Tanaka, Akira Haketa, Shun Yamamuro, Toshiko Suzuki, Hiroki Kobayashi, Yoshinari Hatanaka, Takahiro Ueno, Noboru Fukuda, Masanori Abe, Atsuo Yoshino, Masayoshi Som. Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report. Journal of diabetes investigation. vol 9. issue 1. 2018-08-15. PMID:28390105. |
an 80-year-old japanese female diabetes patient treated with insulin therapy was diagnosed with acromegaly, and the somatostatin analog, lanreotide, was given. |
2018-08-15 |
2023-08-13 |
Not clear |
| Erika Tarasco, Petra Seebeck, Svende Pfundstein, Adrian F Daly, Philippe J Eugster, Alan G Harris, Eric Grouzmann, Thomas A Lutz, Christina N Boyl. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine. vol 58. issue 1. 2018-08-01. PMID:28822091. |
somatostatin analogs are widely used to treat conditions associated with hormonal hypersecretion such as acromegaly and metastatic neuroendocrine tumors. |
2018-08-01 |
2023-08-13 |
rat |
| Daniyar Teltayev, Serik Akshulakov, Nurzhan Ryskeldiev, Khalit Mustafin, Lokshin Vyachesla. Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 33. issue sup1. 2018-07-31. PMID:29264984. |
this article is about a clinical case of acromegaly in a 22 years old woman who was operated on using transnasal transsphenoidal approach and received postoperative treatment with somatostatin analog - lanreotide acetate autogel - for six months. |
2018-07-31 |
2023-08-13 |
Not clear |
| H Alibas, K Uluc, P Kahraman Koytak, M M Uygur, N Tuncer, T Tanridag, D Gogas Yavu. Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy. Journal of endocrinological investigation. vol 40. issue 12. 2018-07-30. PMID:28660605. |
evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy. |
2018-07-30 |
2023-08-13 |
Not clear |
| M Albertelli, E Nazzari, S Sciallero, F Grillo, S Morbelli, F De Cian, G Cittadini, E Ambrosetti, A Ciarmiello, D Feron. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of endocrinological investigation. vol 40. issue 11. 2018-06-27. PMID:28550464. |
octreotide and lanreotide, the first-generation somatostatin analogs, successfully control hormone hyperproduction, and related syndromes, in patients with acromegaly and neuroendocrine tumors. |
2018-06-27 |
2023-08-13 |
Not clear |
| Lian Duan, Huijuan Zhu, Bing Xing, Feng G. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center. BMC endocrine disorders. vol 17. issue 1. 2018-06-06. PMID:28874187. |
prolonged preoperative treatment of acromegaly with somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (knosp grades 1-3): a retrospective cohort study conducted at a single center. |
2018-06-06 |
2023-08-13 |
Not clear |